Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 127Carcinoma, Non-Small-Cell Lung 57Squamous Cell Carcinoma of Head and Neck 46Neoplasms 41Head and Neck Neoplasms 38Neoplasm Metastasis 31Pancreatic Neoplasms 15Colonic Neoplasms 14Lung Neoplasms 13Carcinoma, Squamous Cell 13Breast Neoplasms 13Rectal Neoplasms 12Recurrence 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Melanoma 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Carcinoma 6Solid Tumors 5Gastrointestinal Neoplasms 5Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Neoplasms, Squamous Cell 4Laryngeal Diseases 4Advanced Solid Tumor 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Pancreatic Ductal 3Uterine Cervical Neoplasms 2

Interventions

Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Melphalan 1Immunotherapy 1Fentanyl 1Drug Therapy 1Cetuximab 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Appendiceal Neoplasms × Cetuximab × Clear all
NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
48 enrolled
Gastrointestinal

Appendiceal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡